Stifel Financial Corp Verve Therapeutics, Inc. Transaction History
Stifel Financial Corp
- $86.8 Billion
- Q2 2024
A detailed history of Stifel Financial Corp transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 114,564 shares of VERV stock, worth $572,820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
114,564
Previous 113,955
0.53%
Holding current value
$572,820
Previous $1.51 Million
63.05%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding VERV
# of Institutions
174Shares Held
74.8MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$61.7 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$33.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$26.3 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$22.6 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$19.4 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $300M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...